GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Net Interest Income

Hanall Biopharma Co (XKRX:009420) Net Interest Income : ₩256 Mil (TTM As of Mar. 2025)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Hanall Biopharma Co's net interest income for the three months ended in Mar. 2025 was ₩3 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2025 was ₩256 Mil.

Hanall Biopharma Co Net Interest Income Historical Data

The historical data trend for Hanall Biopharma Co's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Net Interest Income Chart

Hanall Biopharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,128.70 694.36 1,405.01 1,163.51 419.35

Hanall Biopharma Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.83 -37.51 168.29 122.74 2.70

Hanall Biopharma Co Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩256 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanall Biopharma Co Net Interest Income Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Net Interest Income
Comparable Companies
XKRX:006280 XKRX:069620 XKRX:237690 XKRX:195940 XKRX:185750 XKRX:003090 XKRX:068760 XKRX:003850 XKRX:086450 XKRX:000640 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Website
http://www.hanall.co.kr
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co Headlines

No Headlines